Evidence map›Paper›PMID 36356111›Full record

ArticleDiabetes care2023

GLP-1 Receptor Agonists and the Risk of Thyroid Cancer.

Julien Bezin, Amandine Gouverneur, Marine Pénichon, Clément Mathieu, Renaud Garrel, Dominique Hillaire-Buys, Antoine Pariente, Jean-Luc Faillie

Abstract read
PubMed Publisher
In one paragraph

Article in Diabetes care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 167 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
167citing papers in PubMed, 6 pooled it
35.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

167 citing papers in PubMed, 6 syntheses or guidelines pooled it, 278 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer.The Journal of clinical endocrinology and metabolism · 2026
    Observational
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

107 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Julien BezinService de Pharmacologie, Pôle de Santé Publique, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.ORCID 0000-0002-2568-1928
Amandine GouverneurService de Pharmacologie, Pôle de Santé Publique, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
Marine PénichonUMR 1219, Pharmacoepidemiology Team, Bordeaux Population Health Research Center, Inserm, University of Bordeaux, Bordeaux, France.
Clément MathieuUMR 1219, Pharmacoepidemiology Team, Bordeaux Population Health Research Center, Inserm, University of Bordeaux, Bordeaux, France.
Renaud GarrelService de Chirurgie ORL, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
Dominique Hillaire-BuysDépartement de Pharmacologie Médicale et Toxicologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
Antoine ParienteService de Pharmacologie, Pôle de Santé Publique, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
Jean-Luc FaillieDépartement de Pharmacologie Médicale et Toxicologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
Université de Bordeaux · FRCentre Hospitalier Universitaire de Montpellier · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine whether use of glucagon-like peptide 1 (GLP-1) receptor agonists (RA) is associated with increased risk of thyroid cancer. RESEARCH DESIGN AND

methodsA nested case-control analysis was performed with use of the French national health care insurance system (SNDS) database. Individuals with type 2 diabetes treated with second-line antidiabetes drugs between 2006 and 2018 were included in the cohort. All thyroid cancers were identified through hospital discharge diagnoses and medical procedures between 2014 and 2018. Exposure to GLP-1 RA was measured within the 6 years preceding a 6-month lag-time period and considered as current use and cumulative duration of use based on defined daily dose (≤1, 1 to 3, >3 years). Case subjects were matched with up to 20 control subjects on age, sex, and length of diabetes with the risk-set sampling procedure. Risk of thyroid cancer related to use of GLP-1 RA was estimated with a conditional logistic regression with adjustment for goiter, hypothyroidism, hyperthyroidism, other antidiabetes drugs, and social deprivation index.

resultsA total of 2,562 case subjects with thyroid cancers were included in the study and matched with 45,184 control subjects. Use of GLP-1 RA for 1-3 years was associated with increased risk of all thyroid cancer (adjusted hazard ratio [HR] 1.58, 95% CI 1.27-1.95) and medullary thyroid cancer (adjusted HR 1.78, 95% CI 1.04-3.05).

conclusionsIn the current study we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 1-3 years of treatment.

Indexed as

Diabetes Mellitus, Type 2Thyroid NeoplasmsGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsHumansHypoglycemic AgentsGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Identifiers

PMID36356111
OpenAlexW4308701204

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.